title: Oestrogen promotes coronary angiogenesis even under normoxic conditions.
abstract: Angiogenic therapy is one of the new treatments of ischaemic heart disease. Oestrogen has angiogenic properties under hypoxic condition, and if oestrogen also induces angiogenesis under normoxic condition, it could be used in combination with other angiogenic therapies in the treatment of ischaemic heart disease. In this study, we evaluated the angiogenic effect of high-dose oestrogen treatment in normoxic rat heart tissue. Fifty-two ovariectomized rats were randomized in oestrogen-treated and control groups. 17beta-oestradiol (1 mg/week) and normal saline (1 mg/week) were administered intramuscularly in the treatment and control groups for 2 months. After that, coronary capillary density and coronary vessel permeability were measured. The serum vascular endothelial growth factor (VEGF) level was also measured before and after the treatment. The results indicate that coronary capillary density (number of capillary per square millimetre) and coronary vessel permeability (fluorescence intensity) were significantly higher in the oestrogen-treated group than in the control group (628 +/- 26 per mm(2) versus 540 +/- 26 per mm(2); P < 0.05 and 207 +/- 10 versus 147 +/- 19 per gram tissue; P < 0.05). Oestrogen treatment increased serum VEGF level in the oestrogen-treated group compared to the control group (52 +/- 3 versus 33 +/- 6 pg/ml; P < 0.05), but interestingly VEGF was also increased in the control group after placebo treatment. It seems that high-dose oestrogen administration has angiogenic properties even in normoxic conditions. These angiogenic properties may result from oestrogen's direct effect on VEGF or other mechanisms, such as endothelial progenitor cell mobilization. Because of the broad effect of oestrogen on angiogenic growth factors and endothelial cells, more studies are required to clarify angiogenic properties of high-dose oestrogen.
authors.affiliation: Applied Physiology Research Center and Department of Physiology, Isfahan University of Medical Sciences, Isfahan, Iran. nematbakhsh@gmail.com
authors.forename: Mehdi
authors.initials: M
authors.lastname: Nematbakhsh
authors.forename: Mehrzad
authors.initials: M
authors.lastname: Ghadesi
authors.forename: Marzieh
authors.initials: M
authors.lastname: Hosseinbalam
authors.forename: Majid
authors.initials: M
authors.lastname: Khazaei
authors.forename: Marjan
authors.initials: M
authors.lastname: Gharagozloo
authors.forename: Marjan
authors.initials: M
authors.lastname: Gharagozlo
authors.forename: Gholamreza
authors.initials: G
authors.lastname: Dashti
authors.forename: Parvin
authors.initials: P
authors.lastname: Rajabi
authors.forename: Shahram
authors.initials: S
authors.lastname: Rafieian
mesh_terms: D043925:Angiogenesis Inducing Agents / Q000494:pharmacology*; D000818:Animals; D002196:Capillaries / Q000502:physiology; D002199:Capillary Permeability / Q000187:drug effects; D003331:Coronary Vessels / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000494:pharmacology*; D004967:Estrogens / Q000494:pharmacology*; D005260:Female; D066298:In Vitro Techniques; D007273:Injections, Intramuscular; D010052:Ovariectomy; D051381:Rats; D017208:Rats, Wistar; D042442:Vascular Endothelial Growth Factors / Q000097:blood
chemical_list: D043925:Angiogenesis Inducing Agents; D004967:Estrogens; D042442:Vascular Endothelial Growth Factors; D004958:Estradiol